Skip to contentPERRY GREGORY D — IMMUNOGEN INC insider: 122 transactions · InsiderLensPERRY GREGORY D
- Chief Financial Officer & PFO at Merus N.V. · on record since Jun 15, 2023
- Chief Financial Officer at IMMUNOGEN INC · on record since Jan 12, 2009
- Director at Federal Services Acquisition CORP · on record since Feb 27, 2012
- See Remarks at Aegerion Pharmaceuticals, Inc. · on record since Nov 30, 2016
- See Remarks at QLT INC/BC · on record since Dec 27, 2016
- Interim CFO at Design Source, Inc. · on record since Sep 30, 2013
- Chief Financial and Business at Eleven Biotherapeutics, Inc. · on record since Feb 5, 2014
- Director at ADVANCED CELL TECHNOLOGY, INC. · on record since Jan 5, 2015
- See Remarks at Aegerion Pharmaceuticals, Inc. · on record since Feb 17, 2016
- Director at Kala Pharmaceuticals, Inc. · on record since Mar 2, 2018
- Director at Merus N.V. · on record since Jan 2, 2020
- Chief Financial Officer at Finch Therapeutics Group, Inc. · on record since Mar 18, 2021
- Sr. VP - Finance & CFO at TRANSKARYOTIC THERAPIES INC · on record since Jul 29, 2005
Insider trading activity of PERRY GREGORY D
- Transactions on record
- 122
- since Mar 26, 2004
- Open-market buys
- 0
- Open-market sells
- 7
- $953.7K
- Companies traded
- 11
- last filing Dec 12, 2025
Figures computed from official regulatory filings — methodology.
Companies where PERRY GREGORY D has traded
- Merus N.V.18 tx · Dec 12, 2025
- Kala Pharmaceuticals, Inc.17 tx · Jun 17, 2025
- Finch Therapeutics Group, Inc.2 tx · Feb 28, 2022
- QLT INC/BC5 tx · $6.7K · May 11, 2017
- Aegerion Pharmaceuticals, Inc.10 tx · Nov 30, 2016
- ADVANCED CELL TECHNOLOGY, INC.14 tx · $182K · Feb 11, 2016
- Eleven Biotherapeutics, Inc.1 tx · Feb 27, 2015
- Federal Services Acquisition CORP16 tx · Oct 1, 2014
- Design Source, Inc.1 tx · Jan 2, 2014
Track record of PERRY GREGORY D
Insufficient history for a statistical track record (fewer than 5 open-market buys).
Transaction history of PERRY GREGORY D
Co-insiders of PERRY GREGORY D
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
28 tx · $8.7M · Sep 11, 2013
Chan Barbara YAegerion Pharmaceuticals, Inc. +1
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Dec 12, 2025 | OtherD | -17,000 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -14,414 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -6,120 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -372,924 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -100,000 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -16,604 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -4,983 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -5,650 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -8,500 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -8,631 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -107,300 | 0.00 USD | $0 | SEC |
| Jun 17, 2025 | AwardD | 5,450 | 0.00 USD | $0 | SEC |
| Jun 17, 2025 | Award | 2,450 | 0.00 USD | $0 | SEC |
| Jan 31, 2025 | AwardD | 100,000 | 0.00 USD | $0 | SEC |
| Jun 12, 2024 | AwardD | 3,150 | 0.00 USD | $0 | SEC |
| Jun 12, 2024 | Award | 1,400 | 0.00 USD | $0 | SEC |
| May 9, 2024 | AwardD | 107,300 | 0.00 USD | $0 | SEC |
| Jun 23, 2023 | AwardD | 7,808 | 0.00 USD | $0 | SEC |
| Jun 23, 2023 | Award | 1,100 | 0.00 USD | $0 | SEC |
| Jun 23, 2023 | AwardD | 2,500 | 0.00 USD | $0 | SEC |
| Jun 23, 2023 | Award | 5,856 | 0.00 USD | $0 | SEC |
| Jun 15, 2023 | AwardD | 372,924 | 0.00 USD | $0 | SEC |
| Jun 12, 2023 | AwardD | 14,414 | 0.00 USD | $0 | SEC |
| Jun 2, 2023 | OtherD | -800 | — | — | SEC |
| Jun 2, 2023 | OtherD | -420 | — | — | SEC |